Mirum Pharma COO sells 2,631 shares for taxes

Mirum Pharmaceuticals President and COO Peter Radovich reported a sale of company common stock in a Form 4 filing.

Rhea-AI Filing Summary

Mirum Pharmaceuticals President and COO Peter Radovich reported a sale of company common stock in a Form 4 filing. On February 2, 2026, he sold 2,631 shares of common stock at an average price of $103.3035 per share. According to the footnote, the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. After this transaction, he beneficially owned 20,655 shares of Mirum Pharmaceuticals common stock directly.

Insider Trade Summary

Net Seller: 2,631 shares

Net Sell 1 txn

Insider Radovich Peter

Role PRESIDENT AND COO

Sold 2,631 shs ($272K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,631	$103.3035	$272K

Holdings After Transaction: Common Stock — 20,655 shares (Direct)

Footnotes (1)

1. F1. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Mirum Pharmaceuticals (MIRM) report for its President and COO?

Mirum Pharmaceuticals reported that President and COO Peter Radovich sold 2,631 shares of common stock. The transaction took place on February 2, 2026, and was disclosed in a Form 4 insider filing under Section 16(a) of the Securities Exchange Act of 1934.

How many Mirum Pharmaceuticals shares did Peter Radovich sell, and at what price?

Peter Radovich sold 2,631 shares of Mirum Pharmaceuticals common stock. The shares were sold at an average price of $103.3035 per share. This specific trade and pricing are detailed in Table I of the Form 4 insider transaction report filed with the SEC.

Why were Peter Radovich’s Mirum Pharmaceuticals shares sold in this Form 4 filing?

The shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. This explanation appears in the footnote, which states the sale’s purpose, indicating the transaction was connected to equity compensation rather than a discretionary open-market sale.

How many Mirum Pharmaceuticals shares does Peter Radovich own after this transaction?

After the reported sale, Peter Radovich beneficially owned 20,655 shares of Mirum Pharmaceuticals common stock. The Form 4 states this post-transaction holding in the column for “Amount of Securities Beneficially Owned Following Reported Transaction(s)” and notes the ownership form as direct.

What is the role of Peter Radovich at Mirum Pharmaceuticals mentioned in the filing?

The filing lists Peter Radovich as an officer of Mirum Pharmaceuticals with the title “PRESIDENT AND COO.” This designation appears in the relationship section, which identifies him as an executive officer rather than a director or 10% owner for purposes of this insider report.

What type of security was involved in Peter Radovich’s reported transaction?

The transaction involved Mirum Pharmaceuticals common stock, classified as a non-derivative security in Table I. No derivative securities such as options or warrants are reported in Table II of this Form 4, which is shown as empty in the provided content.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 09:45 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Radovich Peter

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND COO

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		2,631	D	$103.3035	20,655	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

	/s/ Judit Ryvkin, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.